Neuromuscular

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 30, 2020.

In part 2 of this interview, Elias Kouchakji, MD, gives perspective on pamrevlumab’s unique pathway as a Duchenne muscular dystrophy treatment nearing the end of the clinical pipeline.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 23, 2020.

The senior vice president of clinical development, drug safety, and pharmacovigilance at FibroGen provides details of the phase 3 LELANTOS trial of pamrevlumab in Duchenne muscular dystrophy.

Experts in the diagnosis and treatment of Duchenne muscular dystrophy share their perspectives on the complex care of this patient population in the NeurologyLive® Insights series “Management of Duchenne Muscular Dystrophy.”

Study results suggest daxibotulinumtoxinA has the potential to reduce the frequency of cervical dystonia treatments by up to 50% annually.

Elias Kouchakji, MD, provides details of the phase 3 LELANTOS study of novel antibody pamrevlumab for the treatment of Duchenne muscular dystrophy.

Here's what is coming soon to NeurologyLive.

The use of real-time quaking-induced conversion and protein misfolding cyclic amplification assays accurately allowed researchers to differentiate synucleinopathies from nonsynucleinopathies.

Neurology News Network for the week ending October 17, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 16, 2020.

The combination agent resulted in a 44% lower risk of death for patients with ALS, with a 6.5-month longer median survival compared with placebo.

The senior vice president of clinical development, drug safety, and pharmacovigilance at FibroGen discussed why the representation of non-ambulatory patient populations is necessary in DMD trials.

The senior vice president of clinical development, drug safety, and pharmacovigilance at FibroGen discussed why turning Duchenne muscular dystrophy into a chronic disease rather than a fatal one, is a top priority.

Italfarmaco is expected to report topline data from the phase 3 EPYDIS trial in June 2022.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending October 10, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 9, 2020.

Nearly two-thirds of patients achieved developmental motor milestones not observed in the natural history of SMA Type 1 at a mean duration of follow-up of 10.6 months.

Results from a 24-week phase 2a trial and its 2-year extension suggest that patients taking vamorolone experienced motor outcome improvements compared to corticosteroid-naïve individuals.

Here's what is coming soon to NeurologyLive.

Solid Biosciences noted that its response to the agency requests for further information about manufacturing as well as updated safety and efficacy data on all dosed patients led to the lift.

The results confirmed that roughly almost 15% of cases are linked to genes and ultimately led to recommendations for more tailored treatments of 3 patients.